Adverum Biotechnologies, Inc.
ADVM
$3.08
$0.051.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -72.22% | -72.22% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -72.22% | -72.22% | -100.00% |
| Cost of Revenue | 61.57% | 25.81% | -0.57% | -17.94% | -20.56% |
| Gross Profit | -60.10% | -24.42% | -2.92% | 15.48% | 17.09% |
| SG&A Expenses | 34.85% | 48.37% | 40.77% | 16.26% | 16.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.14% | 35.70% | 16.60% | -5.46% | -6.80% |
| Operating Income | -48.36% | -34.92% | -19.08% | 3.57% | 4.29% |
| Income Before Tax | -52.83% | -36.17% | -17.95% | 9.15% | 9.78% |
| Income Tax Expenses | -- | -- | -- | -1,631.08% | -1,608.11% |
| Earnings from Continuing Operations | -54.26% | -37.41% | -18.99% | 10.10% | 10.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.26% | -37.41% | -18.99% | 10.10% | 10.67% |
| EBIT | -48.36% | -34.92% | -19.08% | 3.57% | 4.29% |
| EBITDA | -51.37% | -37.75% | -21.57% | 1.68% | 2.82% |
| EPS Basic | 4.51% | 27.23% | 39.68% | 42.32% | 31.02% |
| Normalized Basic EPS | 5.64% | 27.95% | 40.20% | 39.06% | 27.53% |
| EPS Diluted | 4.51% | 27.23% | 39.68% | 42.32% | 31.02% |
| Normalized Diluted EPS | 5.64% | 27.95% | 40.20% | 39.06% | 27.53% |
| Average Basic Shares Outstanding | 45.47% | 78.64% | 96.15% | 69.97% | 43.71% |
| Average Diluted Shares Outstanding | 45.47% | 78.64% | 96.15% | 69.97% | 43.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |